Generics

News Generics

• European Medicines Agency update on Diane 35 and generics used in the treatment of acne

  The French medicines agency announced its plan to suspend the marketing authorisation for Diane 35 and its generics for acne treatment in France. These medicines are widely used across Europe. They have been authorised at the level of individual Member States for many years. In France, they are only more

• Watson Completes Actavis Acquisition

  Watson Pharmaceuticals, Inc. announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion.  The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. Watson funded the tran more

• Developing Countries and Generic Drug Firms Shaking Up the Pharma Industry

  Constricted budgets, the ‘patent cliff’ and the rise of emerging economies are forcing pharmaceutical companies to seriously reassess business strategies, finds a new report by healthcare industry analyst firm GlobalData. According to GlobalData’s 2012 Pharmaceutical Benchmark Report, the major phar more

White papers Generics

• Frost & Sullivan's Global PharmAlliance 2005: Becoming the Partner of Choice
  

  Looking at the increasing trend towards partnerships and alliances in the pharmaceutical industry, Frost & Sullivan a global growth consulting company had organized a premium conference, "Global PharmAlliance 2005 - Becoming the partner of choice" in Mumbai (India). The two day event focused on giving an insight into the world of partnerships and alliances through... more

• Outsourcing R&D Innovation takes on New Meaning
  

  Innovative drugs are the lifeblood of pharmaceutical companies, but the cost of developing them is rising to unsustainable levels. Pharma executives are already saying that as the economy falters, they foresee bleak prospects and mergers unless their companies get more innovative drugs into their pipelines. The clock is ticking on the race to increase productivity, as key patents worth a projected $30 billion in revenue will expire between 2010 and 2013, opening the floodgates to competition from generics, according to Barbara Ryan, an analyst at Deutsche Bank. This imperative is propelling increased outsourcing of R&D operations as companies trim overcapacity. more

• Outsourcing in Pharmaceutical Industry

  Pharmaceutical industry is constantly undergoing a change. In the past pharmaceuticals had a different strategy, companies use to build all the products internally and confine access to information or resources to third parties. The past situation is changing; in-house resources are getting exhausted with a very thin product pipeline and in addition many drugs are going off patent by 2008 hampering company sales and competitiveness. It takes $800 million and 20 years for... more

Publications Generics

• Pharmaceuticals, Vol. 5, Pages 1393-1408: Biosimilars: Company Strategies to Capture Value from the Biologics Market

  Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to more

• Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions

  Background: Multiple reforms have been introduced in the Republic of Srpska to enhance prescribing efficiency. Objectives: First, assess their influence on utilization and expenditure on proton-pump inhibitors, statins and renin–angiotensin inhibitor drugs. Second, assess whether the Republic can ob more

• Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified ...

  Purpose The objective of this study was to compare different methods of adjusted indirect comparisons that can be used to investigate the relative bioavailability of different generic products. To achieve this goal, generic artemether/lumefantrine 20/120 mg tablets that have been prequalified by the more

Market studies Generics

• Uzbekistan Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Uzbekistan’s pharmaceutical market remains one of the fastest growing in the Central and Eastern Europe (CEE) region and its population and currently low levels of per capita pharmaceutical spending gives it the greatest long-term growth potential of any Central Asian market. BMI forecasts more

• Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market

  GBI Research’s new report, “Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market”, presents various tools and strategies which can accelerate a drug to the market. In this report, GBI Research has studied various hurdles at diff more

• Congress on Track to Overcome Partisan Gridlock and Keep the FDA Afloat

  Introduction GlobalData's analysis alert "Congress on Track to Overcome Partisan Gridlock and Keep the FDA Afloat" analyzes legislation recently passed by the United States Senate updating the Prescription Drug User Fee Act (PDUFA) and related provisions, which are set to expire at the end of Sept more

Websites Generics